​

NextCure (NXTC) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

NXTC Stock Forecast

NextCure (NXTC) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $20.00, with a high of $20.00 and a low of $20.00. This represents a 147.83% increase from the last price of $8.07.

- $4 $8 $12 $16 $20 High: $20 Avg: $20 Low: $20 Last Closed Price: $8.07

NXTC Stock Rating

NextCure stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (84.62%), 1 Hold (7.69%), 1 Sell (7.69%), and 0 Strong Sell (0.00%).

Buy
Total 13 1 1 11 0 Strong Sell Sell Hold Buy Strong Buy

NXTC Price Target Upside V Benchmarks

TypeNameUpside
StockNextCure147.83%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-11
Avg Price Target-$20.00$20.00
Last Closing Price$8.07$8.07$8.07
Upside/Downside-147.83%147.83%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 26-1---1
Aug, 2612---3
Jul, 2612---3
Jun, 2612---3
May, 2612---3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 15, 2026Emily BodnarH.C. Wainwright$20.00$6.58203.95%147.83%
Jul 15, 2025Edward TenthoffPiper Sandler$15.00$4.76215.13%85.87%
Jun 03, 2024Edward TenthoffPiper Sandler$3.00$1.5297.37%-62.83%
Nov 03, 2022Edward TenthoffPiper Sandler$6.00$2.51139.04%-25.65%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 13, 2026H.C. WainwrightBuyBuyhold
Jul 15, 2026H.C. WainwrightBuyBuyhold
Jul 15, 2025Piper SandlerOverweightOverweighthold
Jun 03, 2024Piper SandlerOverweightOverweighthold
Nov 03, 2022Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

$-30 $-24 $-18 $-12 $-6 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-27.04$-23.88$-19.65---
Avg Forecast$-2.28$-1.92$-1.45$-0.62$-0.50$-0.47
High Forecast$-2.22$-1.82$-1.39$-0.62$-0.50$-0.47
Low Forecast$-2.33$-1.99$-1.53$-0.62$-0.50$-0.47
Surprise %1085.96%1143.75%1255.17%---

Revenue Forecast

$3M $5M $6M $8M $9M $11M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$3.30M$7.00M$10.60M
High Forecast---$3.30M$7.00M$10.60M
Low Forecast---$3.30M$7.00M$10.60M
Surprise %------

Net Income Forecast

$-65M $-54M $-43M $-32M $-21M $-10M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-62.72M$-55.65M$-55.84M---
Avg Forecast$-62.72M$-53.02M$-40.85M$-17.26M$-13.92M$-13.08M
High Forecast$-61.67M$-50.74M$-38.68M$-17.26M$-13.92M$-13.08M
Low Forecast$-64.74M$-55.30M$-42.61M$-17.26M$-13.92M$-13.08M
Surprise %-4.96%36.71%---

NXTC Forecast FAQ

Is NextCure stock a buy?

NextCure stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 1 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that NextCure is a favorable investment for most analysts.

What is NextCure's price target?

NextCure's price target, set by 13 Wall Street analysts, averages $20 over the next 12 months. The price target range spans from $20 at the low end to $20 at the high end, suggesting a potential 147.83% change from the previous closing price of $8.07.

How does NextCure stock forecast compare to its benchmarks?

NextCure's stock forecast shows a 147.83% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for NextCure over the past three months?

  • September 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is NextCure’s EPS forecast?

NextCure's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.62, marking a -96.84% decrease from the reported $-19.65 in 2025. Estimates for the following years are $-0.5 in 2027, and $-0.47 in 2028.

What is NextCure’s revenue forecast?

NextCure's average annual revenue forecast for its fiscal year ending in December 2026 is $3.3M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $7M, and $10.6M for 2028.

What is NextCure’s net income forecast?

NextCure's net income forecast for the fiscal year ending in December 2026 stands at $-17.259M, representing a -69.09% decrease from the reported $-55.844M in 2025. Projections indicate $-13.918M in 2027, and $-13.083M in 2028.